William P. Davey
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William P. Davey has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Aaron M. Roland
Department of Family Medicine , University of California San Francisco , San Francisco , CA , USA
1 shared publication - Alena G. Guggenheim
Comprehensive Pain Center , Oregon Health and Science University , Portland , OR , USA
1 shared publication - Andrew J. Maxwell
Heart of the Valley Pediatric Cardiology, United States
1 shared publication - Ariana D. Buchanan
Peachtree Allergy and Asthma , Atlanta , GA , USA
1 shared publication - Bruce Hoffman
Hoffman Centre for Integrative and Functional Medicine , Calgary , Alberta , Canada
1 shared publication - Dahra D. Perkins
Elevate Health , Portland , OR , USA
1 shared publication
Latest Publications
- Open Access
- 9 April 2020
- Published by Walter de Gruyter GmbH in Diagnosis
- Vol. 8 (2) , 137-152
Diagnosis of mast cell activation syndrome: a global “consensus-2”
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of “mast cell activation syndrome” (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus” (re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as “consensus-2”), resembling “consensus-1” in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by “consensus-2” criteria has potential to be problematic, but underdiagnosis by “consensus-1” criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.
- 9 April 2020
- Published by Walter de Gruyter GmbH in Diagnosis
- Vol. 8 (2) , 137-152
Open AccessDiagnosis of mast cell activation syndrome: a global “consensus-2”
The concept that disease rooted principally in chronic aberrant constitutive and reactive activation of mast cells (MCs), without the gross MC neoplasia in mastocytosis, first emerged in the 1980s, but only in the last decade has recognition of “mast cell activation syndrome” (MCAS) grown significantly. Two principal proposals for diagnostic criteria have emerged. One, originally published in 2012, is labeled by its authors as a “consensus” (re-termed here as “consensus-1”). Another sizable contingent of investigators and practitioners favor a different approach (originally published in 2011, newly termed here as “consensus-2”), resembling “consensus-1” in some respects but differing in others, leading to substantial differences between these proposals in the numbers of patients qualifying for diagnosis (and thus treatment). Overdiagnosis by “consensus-2” criteria has potential to be problematic, but underdiagnosis by “consensus-1” criteria seems the far larger problem given (1) increasing appreciation that MCAS is prevalent (up to 17% of the general population), and (2) most MCAS patients, regardless of illness duration prior to diagnosis, can eventually identify treatment yielding sustained improvement. We analyze these proposals (and others) and suggest that, until careful research provides more definitive answers, diagnosis by either proposal is valid, reasonable, and helpful.